There is still a lack of lack of standardized treatment protocols for pulmonary embolism. This is mainly due to limited data and a lack of reliable risk assessments, one specialist explained.
The Elixir Medical DynamX sirolimus-eluting coronary bioadaptor is designed to improve coronary luminal diameter, help restore hemodynamic modulation and reduce plaque progression in patients with de novo coronary artery lesions.
Compounded semaglutide injectable products are at the heart of these concerns. While the FDA says compounded drugs “can serve an important medical need for patients,” the agency does not approve these new formulations, increasing the risk of complications.
Nearly 130 healthcare groups are urging Congress to pass legislation that would provide relief to U.S. physicians struggling to keep up with wave after wave of payment reductions.
While JenaValve is known for its Trilogy Heart Valve System, a device designed specifically to treat aortic regurgitation, Endotronix specializes in developing heart failure technologies. The news comes after Edwards sold its critical care business for $4.2 billion in June, saying it would double down on its structural heart portfolio.
Most EP clinical study data are from men, Anne Kroman, DO, explained in an interview. This is a significant problem, she said, because heart rhythm issues look quite different in women.
Image courtesy of Dr Norbert Radacsi/University of Edinburgh.
Even grafts that represent the current gold standard for bypass surgeries are associated with high failure rates, researchers noted. They think these 3D-printed blood vessels could provide considerable value.
BiVacor founder Daniel Timms, PhD. Image courtesy of BiVacor.
The BiVACOR technology was designed to serve as a bridge to heart transplant in patients with end-stage heart failure. Based on rotary blood pump technology, it is made of titanium and approximately the size of an adult’s fist.
New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.
![Researchers have developed artificial blood vessels that could be as strong and durable as the real things, publishing their work in Advanced Materials Technologies.[1] The group hopes its work could go on to make a significant impact in care for heart bypass patients.](/sites/default/files/styles/top_stories/public/2024-07/screenshot_2024-07-25_at_2.38.35_pm.png.webp?itok=imSyZnHs)
